
Drugmaker declines FDA request to pull treatment after patient deaths
By Zachary Stieber Contributing Writer Sarepta Therapeutics will not agree to a regulatory request to pause shipments of a treatment for muscular dystrophy in the wake of patient deaths, the pharmaceutical














